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Tissue kallikrein (KLK1) and plasma kallikrein (KLKB1) may regulate the growth and proliferation of tumours of the lung and
pleura, through the generation of kinin peptides that signal through the kinin B1 (BDKRB1) and B2 (BDKRB2)r e c e p t o r s .T h e
development and progression of cancer results from genetic mutations, as well as epigenetic changes that include methylation
of DNA at CpG islands. The aim of this study was to assess whether expression of the kallikrein-kinin genes in lung cancer
and mesothelioma cells is regulated by DNA methylation. Quantitative reverse transcriptase-PCR and immunocytochemistry
showed diﬀerences in the basal expression of the kallikrein-kinin genes and proteins in lung carcinoma and mesothelioma cells,
compared with non-malignant lung epithelial and mesothelial cells, respectively. Following treatment with the demethylating
agent, 5-azacytidine (5-AZA), KLKB1 mRNA expression was consistently increased in both lung carcinoma and mesothelioma
cells, whereas KLK1, BDKRB1 and BDKRB2 mRNA expression was decreased or unchanged. Increased expression of KLKB1
after 5-AZA treatment suggests it may function as a tumour suppressor gene in cancers of the lung and pleura. Studies on DNA
methylation of the kallikrein-kinin genes will enhance understanding of their role in carcinogenesis and provide insights into the
importance of kallikreins as tumour biomarkers.
1.Introduction
Lung carcinoma is one of the most common cancers in both
males and females and is currently the most frequent cause
of cancer mortality worldwide. Lung carcinogenesis is a mul-
tistep process that arises from the accumulation of genetic
and epigenetic modiﬁcations, which lead to the emergence
of invasive cancer cells. There is good evidence that long-
term exposure to cigarette smoke carcinogens causes diﬀuse
injury to the airway mucosal surface, supporting the concept
thatsmokingdrivestheprogressionoflungcarcinogenesisby
inducing DNA fragmentation and constant disruption of the
cell cycle [1]. In addition, epigenetic modiﬁcation of genes
may also contribute to the development and progression of
lung cancer [2, 3].
Malignant mesothelioma develops on the protective
membrane that lines the lung, and results from exposure
to and inhalation of asbestos dust [4]. Asbestos dust ﬁbres
(5–10μm) usually penetrate into the lower respiratory
tract, where they are phagocytosed by macrophages that
migrate out from the lungs into the pleural mesothelium.
These asbestos ﬁbres are insoluble, and because they are
not metabolized, remain in the pleura where they cause
DNA breaks that result in the malignant transformation of
mesothelial cells [5, 6].
Recent reports indicate that members of the serine pro-
tease family, generically known as tissue kallikreins (KLK1-
15), are involved in carcinogenesis due to the induction of
one or more of the kallikrein genes [7–11]. In particular
hk1, the protein product of the classical tissue kallikrein
(KLK1) gene, is known to hydrolyse macromolecules of the
extracellular matrix, thereby promoting the invasiveness and
metastasis of tumour cells [11]. Furthermore, mitogenic
kinin peptides, formed by the proteolytic action of tissue2 Pathology Research International
kallikrein (KLK1) and plasma kallikrein (KLKB1) on the
kininogen (KNG1) substrates, are known to regulate the
growth and proliferation of tumour cells [12–14]. This is
supported by the ﬁnding that the growth of lung small
cell carcinoma cells is inhibited by dimeric kinin receptor
antagonists [15, 16]. The concept that KLK1 and KLKB1
are involved in the development of cancer and enhance the
tumorigenic process is supported by our recent observations
that the KLK1 and KLKB1 proteins are expressed in carcino-
mas of the lung and pleura [17, 18].
Tumours acquire a distinct pattern of genetic modiﬁ-
cations, which are the result not only of heritable disrup-
tion of gene expression but also of epigenetic alterations
[19]. Thus, the development and progression of cancer
is due to both genetic mutations and epigenetic changes
involving DNA methylation and histone modiﬁcations [20].
The best characterized epigenetic modiﬁcation is aberrant
hypermethylation of CpG islands in the promoter regions
of genes, which results in inappropriate gene silencing [21].
The covalent methylation of DNA at CpG islands is catal-
ysed by methyltransferases that methylate C-5 of cytosine
nucleotides. The question whether methylation of DNA is
an important mechanism regulating the expression of the
kallikrein-kinin genes in carcinomas of the lung and pleura
hasnotbeeninvestigatedpreviously.Thisstudywasdesigned
to investigate the expression of mRNA for KLK1, KLKB1,
KNG1,andkininB1 (BDKRB1)andB2 (BDKRB2)receptors,
following treatment of lung cancer and malignant mesothe-
liomacellswiththeDNAdemethylatingagent,5-azacytidine.
2.MaterialsandMethods
2.1. Cell Culture. Nonmalignant transformed bronchial
epithelial cells (BEAS-2B), lung adenocarcinoma cells
(H2126), lung squamous cell carcinoma cells (H520), and
a transformed epithelial-like mesothelial cell line (Met-5A)
were obtained from the American Type Culture Collection
(Manassas, Va, USA). Three malignant mesothelioma cell
lines (LO68, NO36, and JU77) were derived from pleural
eﬀusions collected by thoracentesis of three patients with
malignant pleural mesothelioma. All cells were cultured in
Dulbecco’s Modiﬁed Eagle Medium supplemented with 10%
foetal bovine serum, in a 5% CO2 atmosphere at 37◦C.
2.2. Treatment of Cells with 5-Azacytidine and Extraction of
RNA. Conﬂuent cells were seeded at 3 × 105 cells/well in
6-well culture plates, and after 24h, 5-azacytidine (5-AZA)
(6.25 or 25μM) was added to the cultures, using acetic acid
as the vehicle. Control cultures were treated with acetic acid
alone. Cells were harvested after 24h, and total RNA was
extracted using RNeasy Plus Mini-kits (Qiagen, Melbourne,
Australia). RNA (2μg per sample) was converted to cDNA
using QuantiTect Reverse Transcription kits (Qiagen).
2.3. Quantitative Real-Time PCR. cDNA was ampliﬁed
by quantitative real-time (q)PCR using TaqMan Gene
Ex-pression primer/probes speciﬁc for the KLK1, KLKB1,
BDKRB1, BDKRB2,a n dKNG1 genes, with human 18S
rRNA as an endogenous control (Applied Biosystems, Mel-
bourne, Australia). qPCR was performed on a Bio-Rad
iCycler instrument, using 25μL reactions containing 12.5μL
of 2× TaqMan Universal PCR Master Mix, 8μLo fR N a s e
free H2O (Qiagen), 1.25μL of primer/probe for the gene
of interest, 1.25μL of human 18S rRNA primer/probe, and
2μL of cDNA. The PCR conditions were 95◦C for 15min,
followed by 45 cycles of 94◦C for 15s, 60◦Cf o r3 0 sa n d
72◦C for 30s. The threshold cycles (CT)w e r e
determined for each sample, and relative gene
expression was calculated using the 2−ΔΔCT formula
[22], where ΔΔCT = (CT,target gene − CT,18S rRNA)Sample X −
(CT,target gene −CT,18S rRNA)Sample Y.
For comparisons of basal gene expression, “Sample X”
was the lung cancer or mesothelioma cell line of interest,
and “Sample Y” was the comparator nonmalignant cell line
(BEAS-2B or Met5A, as appropriate). In qPCR experiments
assessing the eﬀects of 5-AZA, relative gene expression
was compared between 5-AZA-treated cells (“Sample X”)
and control cells treated with vehicle alone (“Sample Y”).
Relative gene expression was plotted on histograms as fold
diﬀerences or fold changes.
2.4. Assessment of Protein Expression by Immunoﬂuorescence
Labelling. Cells were seeded in 96-well plates (500–1000
cells/well) and cultured overnight before treatment with 5-
AZA or vehicle (acetic acid) for 24h. Cells were then ﬁxed
with acetone/methanol (1:1, v/v) for 10min, washed with
0.01M PBS, pH 7.4, and nonspeciﬁc binding was blocked
with 10% human serum, 10% goat serum, and Protein Block
(Dako, Melbourne, Australia) for 15min. After washing with
0.01M PBS, pH 7.4, primary antibodies to tissue kallikrein,
plasma kallikrein, kinin B1 receptor, kinin B2 receptor, and
H-kininogen (1:100 dilution in 0.01M PBS with 1% BSA,
pH 7.4) were added and incubated at room temperature
for 3h. After washing (3× 0.01M PBS), AlexaFluor 488-
conjugated anti-rabbit secondary antibody (1:400 dilution)
was added and incubated for 30min in the dark. Cells
were washed (2× 0.01M PBS) and incubated for 15min
with Hoechst 33342 nuclear stain (1:1000 dilution). Cells
were washed (3× 0.01M PBS) and analysed using a GE
In Cell Analyser 1000 microscope and software (Molecular
Discovery Systems, Perth, Australia), which provided semi-
quantitative measurements of immunoﬂuorescence inten-
sity. The immunoﬂuorescence images were edited using
ImageJ software (National Institutes of Health, Bethesda,
Md,USA),andthemeancytoplasmicﬂuorescenceintensities
were plotted as histograms.
2.5. Cytotoxicity of 5-Azacytidine. Cell proliferation assays
were performed using CyQuant cell proliferation kits (Invit-
rogen, Melbourne, Australia). Cells were seeded in 96-
well plates (5000 cells/well) and cultured for 24h before
treatment with 6.25 or 25μM 5-AZA or vehicle (acetic
acid). After 24h cells were washed (2× 0.01M PBS, pH
7.4) and stored at −80◦C for a minimum of 24h. Cells
were thawed at room temperature, and cell lysis buﬀer
containing CyQuant GR dye was added and incubatedPathology Research International 3
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Figure 1: Basal kallikrein-kinin mRNA and protein expression in H2126 lung adenocarcinoma, H520 lung squamous cell carcinoma, and
nonmalignant BEAS-2B lung epithelial cells. (a) Fold diﬀerences in mRNA expression for the tissue kallikrein (KLK1), plasma kallikrein
(KLKB1), kinin B1 receptor (BDKRB1), kinin B2 receptor (BDKRB2), and high molecular weight kininogen (KNG1) genes in H2126 cells
(white bars) and H520 cells (black bars) relative to that in BEAS-2B cells. (b) Mean cytoplasmic expression of the kallikrein-kinin proteins in
BEAS-2B cells (white bars), H2126 cells (hatched bars), and H520 cells (black bars), as assessed by immunoﬂuorescence labelling and image
analysis.
for 2–5min at room temperature. Fluorescence intensities
were quantiﬁed on a Victor2 1420 ﬂuorescence microplate
reader (PerkinElmer, Melbourne, Australia) with excitation
at 485nm and emission at 530nm. Cell proliferation was
quantiﬁed as the fold change in ﬂuorescence intensity in 5-
AZA-treated cells relative to cells treated with vehicle alone.
2.6. Mapping of CpG Islands in the Kallikrein-Kinin Genes.
The DNA sequences of the ﬁve kallikrein-kinin genes were
obtained from the Entrez Gene database (National Center
for Biotechnology Information, Bethesda, Md, USA), and
sequences were reﬁned using the Nucleic Acid Sequence
Massagerprogram (Attotron Biosensor Corporation, Carson
City,Nev,USA).TheCpGislandswerelocatedusingtheCpG
Plot program (European Bioinformatics Institute, Hinxton,
UK). Schematic gene maps were then constructed, showing
promoterregions,introns,exons,andCpGislandswithinthe
ﬁve genes (Figures 5, 6,a n d7).
2.7. Analysis of Data. Data is presented as mean values from
two to three separate experiments; therefore, meaningful sta-
tistical analysis of the data was not possible. However, when
interpreting the results, a 2-fold or greater change in mRNA
expression was considered to be biologically signiﬁcant.
3. Results
3.1. Basal Expression of Kallikrein-Kinin Genes and Proteins
in Lung Carcinoma Cells and Normal Lung Epithelial Cells.
There was much greater expression of mRNA for KLK1 (21-
fold), BDKRB1 (77-fold), BDKRB2 (300-fold), and KNG1
(44-fold), but lower expression of KLKB1 mRNA (2.6-fold),
in H2126 lung adenocarcinoma cells relative to that in
nonmalignant lung epithelial (BEAS-2B) cells (Figure 1(a)).
In contrast, expression of KLK1, BDKRB1,a n dBDKRB2
mRNA was much lower in H520 lung squamous carcinoma
cells (100-, 590-, and 60-fold, resp.) relative to that in BEAS-
2B cells.
Immunoﬂuorescence labelling showed that basal expres-
sion of the kallikrein proteins (hK1, hKB1) and the kinin B1
and B2 receptor proteins was much greater in H520 squa-
mous carcinoma cells than in BEAS-2B cells (Figure 1(b)).
Expression of these proteins was also greater in H2126
adenocarcinoma cells than in BEAS-2B cells. However,
expression of kininogen protein was similar in the two lung
cancer cell lines and in BEAS-2B cells. The relatively greater
expression of hK1, hKB1, and the B1 and B2 receptors, in
H2126 compared with BEAS-2B cells, appeared to parallel
the respective mRNA expression proﬁles in these two cell
types. However, greater expression of hK1 and the B1 and
B2 receptors in H520 cells compared with BEAS-2B cells
contrasted with the lower mRNA expression in H520 cells.
3.2. Eﬀects of 5-Azacytidine on the Expression of Kallikrein-
Kinin Genes in Lung Carcinoma Cells and Normal Lung
Epithelial Cells. BEAS-2B, H2126, and H520 cells were
treated with 6.25 or 25μM 5-AZA for 24h, and mRNA4 Pathology Research International
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Figure 2: Eﬀect of 5-azacytidine (5-AZA) on kallikrein-kinin mRNA expression in H2126 lung adenocarcinoma, H520 lung squamous cell
carcinoma, and nonmalignant BEAS-2B lung epithelial cells. (a) Fold changes in mRNA expression for the tissue kallikrein (KLK1), plasma
kallikrein (KLKB1), kinin B1 receptor (BDKRB1), and kinin B2 receptor (BDKRB2) genes, relative to vehicle control (arbitrarily set at 1),
in BEAS-2B cells treated with 6.25μM (white bars) or 25μM( b l a c kb a r s )5 - A Z A .( b )F o l dc h a n g e si nm R N Ae x p r e s s i o nf o rt h eKLK1,
KLKB1, BDKRB1, BDKRB2, and high molecular weight kininogen (KNG1) genes, relative to vehicle control (arbitrarily set at 1), in H2126
cells treated with 6.25μM (white bars) or 25μM (black bars) 5-AZA. (c) Fold changes in mRNA expression for the KLK1, KLKB1, BDKRB1,
BDKRB2,a n dKNG1 genes, relative to vehicle control (arbitrarily set at 1), in H520 cells treated with 6.25μM (white bars) or 25μM( b l a c k
bars) 5-AZA.
expression for the KLK1, KLKB1, BDKRB1, BDKRB2, and
KNG1 genes was assessed, relative to that in control cells
treated with vehicle (Figures 2(a)–2(c)). Treatment of BEAS-
2 Bc e l l sw i t h6 . 2 5o r2 5μM 5-AZA decreased expression of
KLK1, BDKRB1,a n dBDKRB2 mRNA by >2-fold relative
to control, whereas expression of the KLKB1 mRNA was
unchanged (Figure 2(a)). Treatment of H2126 cells with 5-
AZA increased the expression of KLKB1 and decreased the
expressionofBDKRB1by>2-foldrelativetocontrol,whereas
expression of the other genes was relatively unaﬀected
(Figure 2(b)). In H520 cells, the most obvious eﬀect of
treatment with 25μM 5-AZA was the marked increase (>40-
fold) in BDKRB2 expression (Figure 2(c)). Expression of
KLK1, KLKB1, BDKRB1,a n dKNG1 mRNA in H520 cells
was also increased by >2-fold relative to control, following
t r e a t m e n tw i t he i t h e r6 . 2 5o r2 5μM 5-AZA.Pathology Research International 5
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Figure3:Basalkallikrein-kininmRNAandproteinexpressioninJU77,NO36,andLO68malignantmesotheliomacellsandinnonmalignant
Met5A mesothelial cells. (a) Fold diﬀerences in mRNA expression for the tissue kallikrein (KLK1), plasma kallikrein (KLKB1), kinin B1
receptor (BDKRB1), and kinin B2 receptor (BDKRB2) genes in JU77, NO36, and LO68 cells, relative to that in Met5A cells (arbitrarily set
at 1). (b) Mean cytoplasmic expression of tissue kallikrein (TK), plasma kallikrein (PK), kinin B1 receptor (B1R), kinin B2 receptor (B2R),
and high molecular weight kininogen (HK) in Met5A, JU77, NO36, and LO68 cells, as assessed by immunoﬂuorescence labelling and image
analysis.
3.3. Basal Expression of Kallikrein-Kinin Genes and Proteins
in Malignant Mesothelioma Cells and Normal Mesothelial
Cells. Basal mRNA expression for the kallikrein-kinin genes
in malignant mesothelioma cells (JU77, NO36, and LO68)
was compared with that in the nonmalignant transformed
mesothelial (Met-5A) cell line. KLK1 mRNA expression was
greater in NO36 (>50-fold), LO68 (>30-fold), and JU77
cells (>2-fold) compared with Met-5A cells (Figure 3(a)).
Similarly, basal KLKB1 mRNA expression was greater in
JU77 (>45-fold), NO36 (>20-fold), and LO68 cells (10-
fold) compared with Met-5A cells. Expression of BDKRB1
and BDKRB2 mRNA was similar in Met-5A cells and the
malignant mesothelioma cells.
Basal expression of the kallikrein-kinin proteins in the
malignant mesothelioma and Met-5A cells, as assessed by
immunoﬂuorescence labelling and image analysis, is shown
in Figure 3(b). Expression of hK1, hKB1, and the kinin B1
and B2 receptor proteins was greater in JU77, NO36, and
LO68mesotheliomacellscomparedwithnonmalignantMet-
5A mesothelial cells.
3.4. Eﬀects of 5-Azacytidine on the Expression of Kallikrein-
Kinin Genes in Malignant Mesothelioma Cells and Normal
Mesothelial Cells. Met-5A, JU77, NO36, and LO68 cells
were treated with 6.25 or 25μM 5-AZA, and expression
of KLK1, KLKB1, BDKRB1, BDKRB2,a n dKNG1 mRNA
was assessed, relative to that in control cells treated with
vehicle (Figures 4(a)–4(d)). In Met-5A cells, BDKRB1
mRNA expression was decreased (>8-fold) after treatment
with 25μM 5-AZA, but expression of the other genes was
relatively unchanged (Figure 4(a)). In JU77 cells, treatment
with both 6.5 and 25μM 5-AZA decreased BDKRB1 and
BDKRB2 expression but increased KLKB1 expression by
>2-fold (Figure 4(b)). Treatment of NO36 and LO68 cells
with 25μM5 - A Z Ar e s u l t e di nm a r k e dd e c r e a s e s( 1 0 -t o
70-fold) in the expression of KLK1, BDKRB1, BDKRB2,a n d
KNG1 mRNA (Figures 4(c) and 4(d)). However, KLKB1
mRNA expression was increased >5-fold on treatment of
N O 3 6c e l l sw i t h6 . 2 5μM 5-AZA.
3.5. Cytotoxicity of 5-Azacytidine. Cell proliferation assays
were performed to determine whether 5-AZA had any
cytotoxic eﬀects on the growth of the nonmalignant and car-
cinoma cells of the lung and pleura, which might indirectly
alter gene expression. The results showed that at concentra-
tions of 6.25 and 12.5μM 5-AZA had no signiﬁcant eﬀect on
the proliferation of any of the cell types (data not shown).
4. Discussion
Thedevelopmentofcancerisassociatedwithgenemutations
and epigenetic dysregulation of the nucleosome. Epigenetic
modiﬁcations cause changes in gene expression without
changes in the DNA sequence, with DNA methylation
and histone deacetylation being the primary epigenetic
mechanisms. In tumours, about 60 to 70% of genes are
methylated, resulting in silencing of these genes. Reversal of
the methylation of promoter and/or transcription sites can
be achieved by the use of demethylating agents such as 5-
AZA or DNA methyltransferase inhibitors.
We have previously shown that hK1, hKB1, and the
kinin B1 and B2 receptors are diﬀerentially expressed in lung
cancers and malignant mesotheliomas [17, 18]. Therefore,
as a ﬁrst step to understanding whether epigenetic modiﬁ-
cations, and speciﬁcally DNA methylation, may contribute
to the diﬀerential expression of the kallikrein-kinin genes in
carcinomas of the lung and pleura, this study focused on
the eﬀects of the demethylating agent, 5-AZA, on mRNA6 Pathology Research International
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Figure 4: Eﬀect of 5-azacytidine (5-AZA) on kallikrein-kinin mRNA expression in nonmalignant Met5A mesothelial cells and JU77, NO36,
andLO68malignantmesotheliomacells.(a)FoldchangesinmRNAexpressionfortissuekallikrein(KLK1),plasmakallikrein(KLKB1),kinin
B1 receptor (BDKRB1), kinin B2 receptor (BDKRB2), and high molecular weight kininogen (KNG1), relative to vehicle control (arbitrarily
set at 1), in Met5A cells treated with 6.25μM (white bars) or 25μM (black bars) 5-AZA. (b) Fold changes in mRNA expression for KLK1,
KLKB1, BDKRB1,a n dBDKRB2, relative to vehicle control (arbitrarily set at 1), in JU77 cells treated with 6.25μM (white bars) or 25μM
(black bars) 5-AZA. (c) Fold changes in mRNA expression for KLK1, KLKB1, BDKRB1, BDKRB2,a n dKNG1, relative to vehicle control
(arbitrarily set at 1), in NO36 cells treated with 6.25μM (white bars) or 25μM (black bars) 5-AZA. (d) Fold changes in mRNA expression
for KLK1, KLKB1, BDKRB1, BDKRB2,a n dKNG1, relative to vehicle control (arbitrarily set at 1), in LO68 cells treated with 6.25μM (white
bars) or 25μM (black bars) 5-AZA.
expression for the kallikrein-kinin genes in lung carcinoma
and malignant mesothelioma cells.
4.1. Basal Expression of the Kallikrein-Kinin Genes in Car-
cinoma Cells of the Lung and Pleura. In the present study,
expression of the kallikrein-kinin genes was greater in lung
carcinoma and malignant mesothelioma cells, as compared
with nonmalignant lung epithelial and pleural mesothelial
cells. Increased basal expression of the kallikrein-kinin genes
in carcinoma cells suggests that they may not be functioning
as tumour suppressor genes, which are usually silenced in
tumours [24], but rather that these are protooncogenes with
the potential to induce tumorigenesis, unless silenced by
DNA methylation. The concept that hK1 is a protooncogenePathology Research International 7
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Figure 5: Schematic map showing putative CpG islands in the KLK1 and KLKB1 genes. (a) The KLK1 gene on chromosome 19q13.3 is
4640bp in length. It has ﬁve exons, ﬁve introns, and two potential promoter regions extending ∼1000 bases upstream of exon 1 and ∼500
bases upstream of exon 5. Mapping indicated a total of six CpG islands in introns 1, 2, 4, and 5, and in exon 5. The most notable is the
CpG island in intron 4 which is 50bp in length and located in a potential promoter region. (b) The KLKB1 gene on chromosome 4q34-35 is
30,954bp in length. It has 15 exons and 14 introns, with a promoter region extending ∼1000 bases upstream of exon 1. Mapping indicated
a total of ﬁve CpG islands in introns 4, 5, 6, and 11.
involved in tumorigenesis in the lung and pleura is sup-
ported by the observations that hK1 and its kinin products
(i) promote metastasis and invasiveness of tumours by
decreasing cell adhesion [11], (ii) stimulate DNA synthesis
by activation of protein kinases [14], (iii) enhance cell
proliferation [25], and (iv) increase vascular permeability
and promote the migration of endothelial cells, which are
hallmarks of angiogenesis [7, 11, 26].
4.2. Expression of Kallikrein-Kinin Proteinsin Carcinoma Cells
of the Lung and Pleura. Greater mRNA expression generally
correlatedwithgreaterexpressionofthekallikrein-kininpro-
teins in the lung cancer and mesothelioma cells, as compared
with nonmalignant lung epithelial and mesothelial cells.
Furthermore, expression of the kallikrein-kinin proteins was
greater in H520 lung squamous carcinoma cells than in
H2126 lung adenocarcinoma cells. Tissue kallikrein and the
B1 and B2 receptor proteins showed the greatest expression,
whereas kininogen protein expression was relatively low in
all three lung cell types. In the mesothelioma cells, basal
expressionoftissuekallikreinwasgreaterthanthatofplasma
kallikrein, and expression of B2 receptor protein was greater
than that of B1 receptor protein. Greater expression of B2
receptor is in keeping with the fact that this receptor is
ubiquitously and constitutively expressed, whereas expres-
sion of the B1 receptor is generally latent or low but is
induced upon cell injury [7, 27]. Kinin B2 receptors on the
cell surface undergo a process of endocytosis upon binding
of the kinin agonist and are recycled back to the surface
of the cell membrane, leading to functional resensitization.
Alternatively,theymaybestoredinthecytoplasmortargeted
for degradation in lysosomes, leading to desensitization
[28, 29]. Therefore expression of B2 receptor protein even
in conditions where mRNA expression is decreased may
be explained by the phenomenon of extensive receptor
endocytosis, cytoplasmic storage, and recycling.
4.3. Eﬀects of 5-Azacytidine on Expression of the Kallikrein-
Kinin Genes in Carcinoma Cells of the Lung and Pleura.
Silencing of gene expression by methylation can be rever-
sed by treatment with demethylating agents such as 5-
azacytidine. Reactivation of genes that are silenced by
methylation indicates that the gene is functional and that
DNA methylation regulates its transcription. Therefore, we
determined whether 5-AZA increased the expression of the
kallikrein-kinin genes in carcinoma cells of the lung and8 Pathology Research International
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pleura. The results indicated that treatment with 5-AZA
increased expression of the KLKB1 gene to some extent in all
lung cancer and malignant mesothelioma cell lines, except
LO68. In H2126 adenocarcinoma and H520 squamous cell
carcinoma cells, as well as JU77 mesothelioma cells, KLKB1
expression was upregulated 4- to 5-fold after treatment with
25μM 5-AZA. These results therefore provide the ﬁrst evi-
dence that the KLKB1 gene is downregulated or silenced by
aberrant methylation in carcinomas of the lung and pleura,
and that KLKB1 may function as a tumour suppressor gene
in these carcinomas. It is interesting to note that more than
30 years ago, Koppelmann et al. [30] observed that increased
levels and activity of plasma kallikrein were associated with
suppression of the growth of ﬁbrosarcomas in hamsters.
In contrast to its eﬀects on KLKB1 gene expression,
5-AZA had variable eﬀects on expression of the other
kallikrein-kinin genes in the diﬀerent tumour cells. 5-AZA
had no consistent eﬀect on KLK1 expression in the lung
carcinoma cells but downregulated KLK1 expression in
NO36 and LO68 mesothelioma cells. Treatment with 5-
AZA resulted in marked upregulation of the BDKRB1 and
BDKRB2 genes in H520 cells but downregulation of these
genes in the other tumour cells. Expression of kininogen
mRNA was variable but tended to be upregulated after 5-
AZA treatment in H520 cells and downregulated in NO36
and LO68 cells. In the mesothelial and mesothelioma cells,
5-AZA generally decreased the expression of the kallikrein-
kinin genes, except for KLKB1, which was upregulated in the
Met-5A, JU77, and NO36 cells.
Decreased expression of some of the kallikrein-kinin
genes after exposure to 5-AZA was unexpected, given that
most previous studies have shown that silenced genes are
reactivated after 5-AZA treatment [31, 32]. However, there
have been reports indicating downregulation of gene expres-
sion after treatment of various cells, including prostate,
breast, ovarian, and lung cancer cells, with DNA methyl-
transferase inhibitors [33–36]. In the study by Pampalakis et
al. [35], treatment with 5-aza-deoxycytidine downregulated
theKLK4andKLK5genesinovariancancercells,whereasthe
same genes were reactivated in similarly treated breast cancer
cells. Therefore distinct epigenetic mechanisms may underlie
the regulation of the various kallikrein-kinin genes inPathology Research International 9
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diﬀerent types of carcinomas. The reason why expression of
somekallikrein-kinin genesis downregulated aftertreatment
with 5-AZA is not known, but possible explanations are that
hypomethylation of CpG islands allows repressor proteins to
access the gene, that there may be indirect epigenetic regu-
lation through demethylation and reactivation of the genes
for silencing proteins or repressor proteins, and that 5-AZA
treatment may have unknown toxic eﬀects on the expression
of some genes. However in the present study, 5-AZA had
no overall toxic eﬀect on lung cancer or mesothelioma cells,
as assessed by cell proliferation assays. It is also possible
that decreased expression of some of the kallikrein-kinin
genes after 5-AZA treatment may be due to the existence of
multiple splice variants or the use of alternative promoters,
as previously observed for KLK6 [37]a n dKLK11 [38].
4.4. Mapping of Putative CpG Islands in the Kallikrein-Kinin
Genes. Although DNA methylation at CpG islands in the
promoter region is known to cause gene silencing [39], the
speciﬁc details of the demethylating eﬀects of 5-AZA on
particular genes are not clear. We therefore mapped the
putative CpG islands in the ﬁve kallikrein-kinin genes and
their relationships with the promoter regions, transcription
factor binding sites, and exons of these genes (Figures 5, 6,
and 7). The maps showed that for the KLK1 and BDKRB2
genes there were CpG islands located in putative promoter
regions. However, the KLKB1, BDKRB1,a n dKNG1 genes
did not appear to have CpG islands located in their putative
promoterregions,raisingthequestionastohowmethylation
might aﬀect the expression of these genes. Besides methy-
lation of CpG islands in promoter regions, it is possible
that regulatory elements of genes are methylated, which may
aﬀect gene expression by blocking essential transcription
factor motifs. Furthermore, gene regulatory elements may
not necessarily be located on the same chromosome or in
close proximity to the genes that they regulate [40]; thus
methylation of CpG islands in regulatory elements at distal
loci may aﬀect expression of the kallikrein-kinin genes.
5. Conclusion
The general suppression of kallikrein-kinin gene expres-
sion, except for the KLKB1 gene, in lung carcinoma and
mesothelioma cells treated with 5-AZA, suggests that these10 Pathology Research International
genes are more likely to function as oncogenes rather
than tumour suppressor genes. KLK1 may function as an
oncogene that transforms normal cells and increases tumour
invasiveness and metastasis. In contrast, the general increase
in expression of KLKB1 after 5-AZA treatment suggests
that it may be a tumour suppressor gene with a critical
role in the formation of new blood vessels in cancers of
the lung and pleura. Further studies involving bisulphite
sequencing and alignment of the resulting sequences are
necessary to detect CpG motifs in the kallikrein-kinin genes
that are diﬀerentially methylated between cancerous and
noncancerous cells.
Advances in the characterization of epigenetic modiﬁca-
tions in cancer cells have improved our understanding of the
mechanisms of gene regulation. DNA methylation may be a
promisingtargetforpotentialtherapeuticstrategies[41],and
demethylating drugs may be beneﬁcial in the treatment of
solid tumours of the lung and pleura. In addition, detection
ofmethylatedDNAinplasma ofcancerpatientsmayprovide
a noninvasive means of diagnosis or monitoring responses to
treatment. Knowledge of the epigenetic changes that occur
in speciﬁc genes should provide us with biomarkers for
following cancer progression, as well as new tools for cancer
therapy.
This paper describes for the ﬁrst time important new
ﬁndings on epigenetic regulation of the kallikrein-kinin
genes by DNA methylation in lung cancer and mesothelioma
cells. Our results show that following treatment with the
demethylating agent, 5-azacytidine, expression of plasma
kallikreinmRNAwasconsistentlyincreasedinbothlungcar-
cinoma and mesothelioma cells, whereas expression of tissue
kallikrein, kininogen, and kinin B1 and B2 receptor mRNA
was either decreased or unchanged. Increased expression
of plasma kallikrein after 5-azacytidine treatment suggests
that it may function as a tumour suppressor gene with an
important and novel role in regulating the vasculature of
cancers of the lung and pleura.
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